Torrent Group enters diagnostics segment with India’s largest reference lab in Navi Mumbai

Torrent Diagnostics

• Torrent Group launches Torrent Diagnostics in Navi Mumbai
• Lab spans 15 disciplines, offers 3,500+ test modalities
• Lab features advanced tech like NGS, MALDI-TOF, and TEM

Did our AI summary help?

Torrent Group, healthcare to energy conglomerate, on Monday said it has entered the fast‑expanding diagnostics market with the launch of Torrent Diagnostics and the opening of what it claims is India’s largest National Reference Laboratory in Navi Mumbai.

The 100,000‑sq‑ft lab spans 15 diagnostic disciplines and more than 3,500 test modalities, handling everything from molecular diagnostics and genomics to digital pathology, microbiology and transplant‑related testing.

The company said the lab is equipped with high‑end platforms including Next‑Generation Sequencing (NGS), MALDI‑TOF, BSL‑3 containment, and has Western India’s first Transmission Electron Microscope (TEM) in a standalone diagnostics lab, positioning Torrent among the most technologically advanced new entrants in the sector.

The company says its reference‑led model will allow it to scale without compromising scientific rigor.

“Diagnostics is a discipline where trust is built through process integrity, scientific depth and consistency over time… we have approached this business with a long‑term perspective, starting with a strong scientific foundation,” said Varun Mehta, Director at Torrent Group, adding that the national reference lab framework establishes governance, validation and quality standards from day one.

Torrent Diagnostics is also investing in patient‑experience layers—including high‑quality patient centres, trained phlebotomists and a digital interface—to differentiate itself in a crowded market.

Torrent’s move mirrors a broader shift in India’s health‑care landscape, where leading pharmaceutical companies are branching into diagnostics to capture adjacent value pools, diversify revenue, and create integrated care ecosystems. Over the past decade, several pharma players have expanded into pathology chains, molecular testing, genomic services and health‑tech‑enabled screening, driven by the recognition that diagnostics—now contributing to over 70 percent of clinical decisions—offers both strategic stickiness with clinicians and a higher growth trajectory than traditional formulations.

Torrent’s entry reinforces the trend of large, capital‑rich healthcare groups building national testing networks anchored in high‑complexity reference labs, a model increasingly seen as essential for scale, standardization and advanced test development.

The launch also aligns with Torrent Group’s push to deepen its healthcare footprint beyond pharmaceuticals, complementing its portfolio of businesses across energy, gas distribution and sports.